Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

LPL is the strongest prognostic factor in a comparative analysis of RNA-based markers in early chronic lymphocytic leukemia

In English

Författare

  • Mohd Arifin Kaderi
  • Meena Kanduri
  • Anne Mette Buhl
  • Marie Sevov
  • Nicola Cahill
  • Rebeqa Gunnarsson
  • Mattias Jansson
  • Karin Ekstrom Smedby
  • Henrik Hjalgrim
  • Jesper Jurlander
  • Gunnar Juliusson
  • Larry Mansouri
  • Richard Rosenquist
Visa allt

Summary, in English

Background The expression levels of LPL, ZAP70, TCL1A, CLLU1 and MCL1 have recently been proposed as prognostic factors in chronic lymphocytic leukemia. However, few studies have systematically compared these different RNA-based markers. Design and Methods Using real-time quantitative PCR, we measured the mRNA expression levels of these genes in unsorted samples from 252 newly diagnosed chronic lymphocytic leukemia patients and correlated our data with established prognostic markers (for example Binet stage, CD38, IGHV gene mutational status and genomic aberrations) and clinical outcome. Results High expression levels of all RNA-based markers, except MCL1, predicted shorter overall survival and time to treatment, with LPL being the most significant. In multivariate analysis including the RNA-based markers, LPL expression was the only independent prognostic marker for overall survival and time to treatment. When studying LPL expression and the established markers, LPL expression retained its independent prognostic strength for overall survival. All of the RNA-based markers, albeit with varying ability, added prognostic information to established markers, with LPL expression giving the most significant results. Notably, high LPL expression predicted a worse outcome in good-prognosis subgroups, such as patients with mutated IGHV genes, Binet stage A, CD38 negativity or favorable cytogenetics. In particular, the combination of LPL expression and CD38 could further stratify Binet stage A patients. Conclusions LPL expression is the strongest RNA-based prognostic marker in chronic lymphocytic leukemia that could potentially be applied to predict outcome in the clinical setting, particularly in the large group of patients with favorable prognosis.

Publiceringsår

2011

Språk

Engelska

Sidor

1153-1160

Publikation/Tidskrift/Serie

Haematologica

Volym

96

Issue

8

Dokumenttyp

Artikel i tidskrift

Förlag

Ferrata Storti Foundation

Ämne

  • Hematology

Nyckelord

  • LPL
  • RNA-based markers
  • chronic lymphocytic leukemia
  • prognosis

Status

Published

ISBN/ISSN/Övrigt

  • ISSN: 1592-8721